
The Open Questions: No Crossover, Sequencing, Resistance, and Where SERDs Fit
The questions in my mind start with sequencing.
Premji: The questions in my mind start with sequencing. We are bringing a very highly active agent earlier — at the first sign of molecular progression rather than clinical or radiographic progression. If you were to sequence it after radiographic progression instead, what would you see? From SERENA-2, we saw a median PFS of about 7 months with single-agent camizestrant after prior endocrine therapy. So if you move SERD exposure later, what do you actually get? The inability to cross over on SERENA-6 — patients in the control arm could not access a SERD after progression — leaves that question open and introduces lead-time bias. We’re hoping to see overall survival data in the future.
Premji: Another question in my mind is about resistance. If we suppress ESR1 earlier — and a SERD is such a powerful endocrine therapy, it binds the ligand-binding domain, makes the receptor structurally unable to dimerize or bind functional domains, and flags it for proteasomal degradation — SERDs are very powerful. If we bring them further up in therapy, what are the next escape pathways we’ll see, and what will the mechanisms of resistance look like? These are all questions we hope to learn more about. What are your questions from SERENA-6?
Hundal: I agree, especially on escape mechanisms as we move these drugs upfront. I was also interested in the toxicity profile. The major side effect was neutropenia in this cohort, which we would expect with the CDK4/6 inhibitor companion. There were episodes of photopsia and bradycardia, but it was reassuring to see that those did not lead to treatment discontinuation. I’m excited to see what comes next and how the overall survival shapes up. What are your thoughts on the no-crossover design?
Premji: That is still the active question in my mind — what happens if you use a SERD after progression. Another question that comes up is that, by design, SERENA-6 continues the same CDK4/6 inhibitor the patient started on. What happens if you switch the CDK4/6 inhibitor at that moment of molecular progression? That is still an open question.
Premji: On tolerability — there is a slight nuance with camizestrant-associated bradycardia, which is generally mild. We may see a patient come through triage with some bradycardia; we should be aware of it, and particularly check EKGs when giving with ribociclib. We’re already used to monitoring EKGs with ribociclib, so it is a small additional check. Overall, camizestrant is fairly well tolerated. The no-crossover design was a key question at the ODAC meeting, and I hope we’ll have additional data in the future to help us decide how to move forward with this class — especially because SERDs are being studied in other settings.
Premji: SERDs are being studied in the adjuvant setting. We’ve had a few trials, including one phase 3 readout, and SERENA-4 is another we hope to see fully in the near future. The use of a SERD with a CDK4/6 inhibitor in the first-line setting in a fully unselected population is maybe not giving us the median PFS benefit past the benchmark we hoped. So the question is where exactly SERDs fit, and for which patients. There are also adjuvant-setting switch trials — ELEGANT and others. So this is still a very active question: where do SERDs fit in the treatment landscape? But exciting times.
Related to this article







